Analyst for Laura Chico's questions to Xenon Pharmaceuticals Inc (XENE) leadership • Q4 2024
Question
An analyst on for Laura Chico at Wedbush Securities asked which patient types would likely be the earliest adopters of Azetukalner: those needing better seizure control or those experiencing mood issues with current therapies.
Answer
President and CEO Ian Mortimer responded that the full Phase III data, including exploratory mood endpoints, will provide more clarity. He noted that patients with uncontrolled seizures often seek solutions for both seizure frequency and comorbidities like mood disorders. Chief Medical Officer Dr. Chris Kenney added that early adoption is also heavily influenced by prescriber patterns and their willingness to use new therapies.